<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04180228</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0456</org_study_id>
    <nct_id>NCT04180228</nct_id>
  </id_info>
  <brief_title>Human Papilloma Virus Vaccination and Chronic Inflammatory Rheumatic Diseases.</brief_title>
  <acronym>HPV-CIR</acronym>
  <official_title>Human Papilloma Virus Vaccination and Chronic Inflammatory Rheumatic Disease. A Cross-sectional Study of Vaccinal Coverage, Barriers and Motivations.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic inflammatory rheumatic disease (CIR) are at increased risk for
      infections. Vaccination is a powerful tool to prevent infections, even in immunocompromised
      patients. Low-risk types of Human papilloma virus (HPV) cause anogenital warts, while high
      risk types are strongly related to pre-malignant cervical abnormalities and cervical cancer.
      HPV vaccines have been developed to prevent these conditions. Human papillomavirus (HPV)
      infections are more prevalent in systemic lupus erythematosus (SLE) patients or other
      auto-immune diseases when compared to the healthy population. In France, despite a
      vaccination available since 2007, rate of vaccination remain low. Although little is known
      about HPV vaccination in SLE, few studies in patients with autoimmune rheumatic diseases
      (AIRDs) have shown that HPV vaccines are safe, and capable to induce an immunogenic response
      in this group of patients. To date, available data suggest that HPV vaccines can be given
      safely to SLE patients. Given the increased incidence of cervical abnormalities due to HPV in
      SLE patients, this vaccination should be encouraged.

      The aim of this study was to assess the vaccination coverage rate in chronically ill girls
      with SLE or idiopathic juvenile arthritis who require a close pediatric specialized follow-up
      vaccination and to understand barriers or motivations for it.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of HPV vaccination (percentage of patients vaccinated).</measure>
    <time_frame>Day 0, Time of intervention (questionnaire)</time_frame>
    <description>We report this information with an item &quot;vaccination for Human papilloma virus&quot;. The proposition of response is &quot;Yes&quot; or &quot;No&quot;. We'll calculate the number of vaccination among the population including in the study.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Idiopathic Juvenile Arthritis</condition>
  <condition>Human Papilloma Virus</condition>
  <arm_group>
    <arm_group_label>Systemic lupus erythematosus</arm_group_label>
    <description>Investigators include in this group all young girls between 11 to 19 years old who accepted to respond to the questionnaire with systemic lupus erythematosus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idiopathic juvenile arthritis</arm_group_label>
    <description>Investigators include in this group all young girls between 11 to 19 years old who accepted to respond to the questionnaire, with idiopathic juvenile arthritis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>self-administred questionnaire</intervention_name>
    <description>On the occasion of a follow-up consultation with referent pediatrician, a self-administred questionnaire is distributed. It will take around ten minutes to the patient and her parents for completing the questionnaire. Questionnaire is anonymous. Participation is free and informed by an information notice. There is a list of items to complete by the patient and her parents. Most of questions are closed-ended. Clinical data are reported : age, level of education, principal disease (SLE or Juvenile arthritis), received treatments. In the questionnaire, it is asked if the patient is vaccinated or not for HPV, and reasons for it.</description>
    <arm_group_label>Idiopathic juvenile arthritis</arm_group_label>
    <arm_group_label>Systemic lupus erythematosus</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Investigators study a French sample of young girls follow-up for systemic lupus
        erythematosus or idiopathic juvenile arthritis. It's a multicenter design.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Young girls older than 11 years old until adult transition

          -  Follow-up for systemic lupus erythematosus (American college of rheumatology
             classification) or idiopathic juvenile arthritis (International League of Associations
             for Rheumatology classification)

          -  Follow-up in a Childen's hospital of Lyon (Hopital Femme Mère Enfant) and Paris
             (Hospital Necker-Enfants Malades, Hôpital Robert Debré)

          -  With no parental opposition to participate

        Exclusion Criteria:

          -  Refusing to participate

          -  Age &lt; 11 years old
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emmanuelle DAVID</last_name>
    <phone>6 74 39 72 50</phone>
    <phone_ext>+33</phone_ext>
    <email>emmanuelle.david01@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine ROUSSET-JABLONSKI, MD</last_name>
    <phone>4 78 56 90 49</phone>
    <phone_ext>+33</phone_ext>
    <email>christine.rousset-jablonski@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Femme Mère Enfant</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexandre BELOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexandre BELOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré, AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Ulrich MEINZER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ulrich MEINZER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necke -, Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Brigitte BADER-MEUNIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Brigitte BADRE-MEUNIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de médecine interne, Centre hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Emmanuelle DAVID</last_name>
      <phone>6 74 39 72 50</phone>
      <phone_ext>+33</phone_ext>
      <email>emmanuelle.david01@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Christine ROUSSET-JABLONSKI, MD</last_name>
      <phone>4 78 56 90 49</phone>
      <phone_ext>+33</phone_ext>
      <email>christine.rousset-jablonski@chu-lyon.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 31, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>November 28, 2019</last_update_submitted>
  <last_update_submitted_qc>November 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

